HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Physician Consultation Prior To Sports Performance Aid Use Urged

This article was originally published in The Tan Sheet

Executive Summary

Consumers should consult physicians or nutrition experts before considering using dietary supplements to enhance athletic performance, a joint position paper from the American Dietetic Association, Dietitians of Canada and American College of Sports Medicine advises.

You may also be interested in...



White House Sports Drug Task Force Preliminary Report Expected Early 2001

Sports nutritional supplements such as androstenedione and ephedrine, which are banned in international Olympic competition but legally available in the U.S., could be subjected to new scrutiny by a national task force on performance-enhancing substances.

Creatine Use Discouraged Due To Sparse Research, Potential AEs

The safety and efficacy of creatine monohydrate has not been established, and young athletes should refrain from taking the supplement until additional research has been conducted, the Healthy Competition Foundation announced May 15.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel